COPENHAGEN, Denmark, December 13 /PRNewswire/ --

- Summary: Genmab has Initiated a Phase II Study of Ofatumumab in Relapsed Diffuse Large B-Cell Lymphoma

Genmab A/S (OMX: GEN) announced today that study centers have been initiated and are ready to enroll patients in a Phase II study of ofatumumab (HuMax-CD20(R)) to evaluate treatment of relapsed Diffuse Large B-Cell Lymphoma (DLBCL) in patients ineligible for or relapsed following a stem cell transplant. Approximately 75 patients will be enrolled in the study which is being conducted under Genmab's collaboration with GlaxoSmithKline (GSK). Genmab will receive a milestone payment of approximately DKK 87.2 million from GSK upon treatment of the first patient in the study, expected in the near future.

PLYMOUTH, England, December 13 /PRNewswire/ --

- How do you Know if you Need to Call the Vet?

- Is it Urgent?

- Can it Wait Until a Normal Working Day?

Vet Help Direct is a free, interactive, online guide to help dog, horse, cat and rabbit owners decide if they need to contact the vet, and if so, how urgently. The website helps to alleviate the 'Can it wait until the next normal working day?' dilemma when faced with an ill or injured animal at night or on a bank holiday. The site is designed and run by British vets and is the first of its kind anywhere on the internet.

COPENHAGEN, Denmark, December 13 /PRNewswire/ --

- Summary: Genmab has Announced Details of a Planned Phase II Study of Ofatumumab to Treat Relapsing Remitting Multiple Sclerosis

Genmab A/S (OMX: GEN) announced today details of a planned Phase II study of ofatumumab (HuMax-CD20(R)) for the treatment of relapsing remitting multiple sclerosis (RRMS). Approximately 324 patients will be enrolled in the study which will be conducted under Genmab's collaboration with GlaxoSmithKline (GSK). The study is expected to begin in the first quarter of 2008.

SAN FRANCISCO, December 13 /PRNewswire/ --

- Italy's leading pay-TV operator renews agreement for OpenTV solutions

OpenTV Corp. (Nasdaq: OPTV), a leading provider of solutions for the delivery of advanced television and cross-platform interactive services, announced today that Sky Italia has entered into a multi-year renewal of its middleware license agreement with OpenTV. Sky Italia is Italy's premier provider of satellite television, offering a variety of programming choices to more than four million subscribers.

REHOVOT, Israel and NEW YORK, December 13 /PRNewswire/ --

- Target Diseases for This Collaboration are Diffuse Large Cell Lymphoma, Transformed Follicular Lymphoma, and Chronic Lymphocytic Leukemia

- Collaboration to Develop MicroRNA-Based Diagnostics Test, Early Detection and Prognosis.

- 43,000 People Will be Diagnosed With These Types of Cancers in 2007 in the US Alone(1)

- MicroRNAs Hold Significant Potential as Highly Sensitive and Specific Biomarkers for Hematological Cancers

- Collaboration Also Will Seek to Identify MicroRNA (miRNA) Targets for Therapeutic Applications

LONDON, December 13 /PRNewswire/ --

Marian Salzman, the world's no. 1 Trendspotter and Chief Marketing Officer at JWT Worldwide, is back for the third year along with Ann Mack, Director of Trendspotting at JWT, with their fascinating annual forecasts for 2008. Marian has previously brought us the metrosexual man, domestic divas, globesity, fortification and wiggers (white kids who want to be black).

Trends covered include Health, Travel, Home, Technology, Fashion and Beauty. (For more detailed information on the trends below and information on many others please see contact details below.)

Researchers at Low Temperature Laboratory and Laboratory of Physics (TKK) and at University of Stony Brook (New York) have potentially solved the problem of accurately defining the ampere. The group has developed a frequency to current converter, the accuracy of which is based on the known charge of an electron and the extreme accuracy in defining frequency. The nanodevice is essentially a single electron transistor which works as a simple single-electron turnstile. Its best performance is achieved at very low temperatures.

Previously, the electric current and its unit, the ampere, have been defined through the classical force induced to two parallel leads carrying the current.

ZURICH, Switzerland, December 13 /PRNewswire/ --

- Player-to-Screen Distribution System to be Added to Six New Product Lines

Minicom is proud to announce the expansion of its partnership with NEC Display Solutions. The joint Minicom and NEC venture began in February of 2006 with the announcement of the integration of the DS Vision 3000 receiver with NEC's Mutleos line of display screens. The partnership will now be enlarged to incorporate Minicom receivers in a total of seven different models of NEC screens.

CALGARY, Canada, December 13 /PRNewswire/ -- SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that Oye Olukotun, MD, MPH, FACC, FAHA, has agreed to join the Board of Directors of the Company. Dr. Olukotun is the co-founder and Chief Medical Officer of VIA Pharmacueticals (NASDAQ: VIAP) a company focused on cardiovascular disease treatments. He will replace Dr. Douglass Given, who is retiring from the Board of SemBioSys after serving for seven years.

Long-lived, wild animals harbor genetic differences that influence how quickly they begin to show their age, according to the results of a long-term study reported in Current Biology. Evidence for the existence of such genetic variation for aging rates—a central tenet in the evolutionary theory that explains why animals would show physiological declines as they grow older—had largely been lacking in natural populations until now, the researchers said.

“We’ve found that individuals differ in their rates of aging, or senescence, and that these differences are (at least in part) caused by genetic effects so they will be inherited,” said Alastair Wilson of the University of Edinburgh.